Antirheumatic Agents: Drugs that are used to treat RHEUMATOID ARTHRITIS.Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)Auranofin: An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.Organogold Compounds: Organic compounds that contain GOLD as an integral part of the molecule. Some are used as ANTIRHEUMATIC AGENTS. The term chrysotherapy derives from an ancient Greek term for gold.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.Gold Sodium Thiomalate: A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Rheumatology: A subspecialty of internal medicine concerned with the study of inflammatory or degenerative processes and metabolic derangement of connective tissue structures which pertain to a variety of musculoskeletal disorders, such as arthritis.Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Arthrography: Roentgenography of a joint, usually after injection of either positive or negative contrast medium.Joints: Also known as articulations, these are points of connection between the ends of certain separate bones, or where the borders of other bones are juxtaposed.Rheumatoid Factor: Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.Arthritis, Psoriatic: A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.ThiomalatesFoot Joints: The articulations extending from the ANKLE distally to the TOES. These include the ANKLE JOINT; TARSAL JOINTS; METATARSOPHALANGEAL JOINT; and TOE JOINT.Anti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Receptors, Tumor Necrosis Factor: Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Hand Joints: The articulations extending from the WRIST distally to the FINGERS. These include the WRIST JOINT; CARPAL JOINTS; METACARPOPHALANGEAL JOINT; and FINGER JOINT.Rheumatic Diseases: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.Tripterygium: A plant genus of the family CELASTRACEAE that is a source of triterpenoids and diterpene epoxides such as triptolide.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.ArthritisSynovitis: Inflammation of a synovial membrane. It is usually painful, particularly on motion, and is characterized by a fluctuating swelling due to effusion within a synovial sac. (Dorland, 27th ed)Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.United States Agency for Healthcare Research and Quality: An agency of the PUBLIC HEALTH SERVICE established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery..." It supersedes the National Center for Health Services Research. The United States Agency for Health Care Policy and Research was renamed Agency for Healthcare Research and Quality (AHRQ) under the Healthcare Research and Quality Act of 1999.Glucocorticoids: A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Synovial Membrane: The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes SYNOVIAL FLUID.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Blood Sedimentation: Measurement of rate of settling of erythrocytes in anticoagulated blood.Anti-Inflammatory Agents: Substances that reduce or suppress INFLAMMATION.Spondylitis, Ankylosing: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Biological Products: Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.Arthritis, Juvenile: Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Product Surveillance, Postmarketing: Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.Peptides, Cyclic: Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).Interleukin 1 Receptor Antagonist Protein: A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Wrist Joint: The joint that is formed by the distal end of the RADIUS, the articular disc of the distal radioulnar joint, and the proximal row of CARPAL BONES; (SCAPHOID BONE; LUNATE BONE; triquetral bone).Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Treatment Failure: A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.Finger Joint: The articulation between the head of one phalanx and the base of the one distal to it, in each finger.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Early Diagnosis: Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Injections, Subcutaneous: Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Immunoconjugates: Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.Adrenal Cortex HormonesProspective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Immunologic Factors: Biologically active substances whose activities affect or play a role in the functioning of the immune system.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Health Status: The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures.Disability Evaluation: Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits.Epidemiologic Methods: Research techniques that focus on study designs and data gathering methods in human and animal populations.Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.C-Reactive Protein: A plasma protein that circulates in increased amounts during inflammation and after tissue damage.Statistics, Nonparametric: A class of statistical methods applicable to a large set of probability distributions used to test for correlation, location, independence, etc. In most nonparametric statistical tests, the original scores or observations are replaced by another variable containing less information. An important class of nonparametric tests employs the ordinal properties of the data. Another class of tests uses information about whether an observation is above or below some fixed value such as the median, and a third class is based on the frequency of the occurrence of runs in the data. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1284; Corsini, Concise Encyclopedia of Psychology, 1987, p764-5)Placebos: Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Physician's Practice Patterns: Patterns of practice related to diagnosis and treatment as especially influenced by cost of the service requested and provided.

Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. (1/3077)

OBJECTIVE: To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA). METHODS: Two hundred twelve patients with early RA (mean duration 1.5 years) were enrolled in a 24-week trial. Patients were stabilized with 1,000 mg naproxen/day and then began a 6-week, double-blind trial comparing treatment with HCQ at 400 mg/day (n = 71), 800 mg/day (n = 71), and 1,200 mg/day (n = 66), followed by 18 weeks of open-label HCQ treatment at 400 mg/day. RESULTS: All patients had mild, active disease at the time of initiation of HCQ treatment (31-43% rheumatoid factor positive; no previous disease-modifying antirheumatic drugs; mean swollen joint count 8.6-10.4). Based on the Paulus criteria, response during the 6-week double-blind portion of the study was 47.97%, 57.7%, and 63.6% in the 400 mg/day, 800 mg/day, and 1,200 mg/day groups, respectively (P = 0.052). Discontinuations for adverse events were dose related (3 in the 400 mg/day group, 5 in the 800 mg/day group, 6 in the 1,200 mg/day group). Most involved the gastrointestinal (GI) system, with the background naproxen treatment possibly contributing. Ocular abnormalities occurred in 17 of 212 patients (8%) but were not dose related. CONCLUSION: Dose-loading with HCQ increased the degree of response at 6 weeks in this group of patients with early, predominantly seronegative RA. Adverse GI events were dose related, while adverse ocular events were not.  (+info)

Inhibition of IL-6 and IL-8 induction from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. (2/3077)

Gold compounds have long been used in the treatment of rheumatoid arthritis (RA). However, their actions in RA have not been clarified. In this study, we examined the effect of one of the monovalent gold compounds, aurothioglucose (AuTG), on the IL-1-induced production of IL-6, IL-8 and granulocyte macrophage colony stimulating factor (GM-CSF) from rheumatoid synovial fibroblasts (RSF) isolated from three RA patients. IL-6 and IL-8 induction but not GM-CSF induction was inhibited in most of the RSF after pretreatment with AuTG. Since gene expression of these cytokines is known to be under the control of a common transcription factor, NF-kappaB, the effect of AuTG on the cellular localization of NF-kappaB (p65 subunit) and on NF-kappaB-DNA binding was examined. Although AuTG treatment did not prevent NF-kappaB nuclear translocation, AuTG blocked the DNA-binding activity of NF-kappaB when examined in vitro. Morphologically, both metal-specific cell staining using p-dimethylaminobenzylidene rhodamine and transmission electron microscopic examinations demonstrated the accumulation of metal gold in the cytoplama and some organella (mitochondria and lysosomes) of the AuTG-treated RSF. These results indicate that one of the anti-rheumatic actions of AuTG might be through its inhibitory action on NF-kappaB.  (+info)

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. (3/3077)

OBJECTIVE: To determine the role of interleukin-1 receptor antagonist (IL-1Ra) in rat adjuvant arthritis and rat type II collagen-induced arthritis, and to compare the efficacy in rat models with that seen in human clinical trials of IL-1Ra. METHODS: Rats with developing adjuvant arthritis or established collagen-induced arthritis were treated with IL-1Ra by continuous infusion in order to determine and maintain efficacious blood levels of this IL-1 inhibitory protein in the rats for comparison with human clinical data. The effects of treatment in the rats were monitored by sequential caliper measurement of the ankle joints, determination of final paw weights, and histologic evaluation with particular emphasis on bone and cartilage lesions. The effects of IL-1Ra on joint swelling and radiographic bone damage in patients with rheumatoid arthritis (RA) in a 6-month trial were compared with the findings in rats. RESULTS: Dramatic differences in the profile of IL-1Ra activity were seen between the 2 groups of rats. Modest antiinflammatory effects were observed in the adjuvant arthritis rats treated with IL-1Ra. However, marked inhibition of bone resorption occurred, even at doses with which antiinflammatory activity was not seen. In contrast, IL-1Ra treatment of rats with established collagen-induced arthritis resulted in nearly complete suppression of all aspects of the disease when adequate blood levels of IL-1Ra were maintained. Treatment of RA patients with IL-1Ra (150 mg daily) resulted in modest inhibition of joint swelling and inhibition of radiographic progression of bone lesions. CONCLUSION: IL-1 appears to be of major importance in mediating the bone resorption that occurs in rat adjuvant arthritis, but is less important in the pathogenesis of periarticular inflammation in this disease. In contrast, IL-1 is of major importance in mediating all aspects of disease progression in rat collagen-induced arthritis. Similar to the response in adjuvant arthritic rats, RA patients treated with IL-1Ra showed only modest antiinflammatory activity, but had evidence of inhibition of progression of bone resorption. However, a comparison of the plasma levels of IL-1Ra in humans and rats suggests that the optimal level of dosing for continuous saturation of IL-1 receptors may not have been achieved in humans, although this was achieved in the rat studies.  (+info)

Effect of its demethylated metabolite on the pharmacokinetics of unchanged TAK-603, a new antirheumatic agent, in rats. (4/3077)

A factor in the dose-dependent pharmacokinetics of ethyl 4-(3, 4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2, 4-triazol-1-yl-methyl)quinoline-3-carboxylate (TAK-603) in rats was shown to be due to the inhibition of metabolic clearance of unchanged TAK-603 by its major metabolite, M-I, in other words, product inhibition. The effect of M-I on the metabolic clearance of TAK-603 was studied using rats continuously infused i.v. with this metabolite at rates of 5.3 and 16.0 mg/h/kg. The total body clearance of TAK-603 was decreased remarkably in M-I-infused rats, and the decline of total body clearance depended on the steady-state plasma concentrations of M-I. The effect of M-I generated from the dosed parent drug on the plasma concentration-time profile of TAK-603 was investigated using bile-cannulated rats after i.v. injection of 14C-labeled TAK-603 at doses of 1 and 15 mg/kg. Elimination rates of TAK-603 from rat plasma increased in the bile-cannulated rats in which systemic M-I levels were reduced by interrupting its enterohepatic circulation. To express, simultaneously, the relationships between TAK-603 and M-I in plasma concentration-time profiles, a kinetic model based on the product inhibition was developed for the bile-cannulated rats. A good agreement between calculated curves and the observed concentrations of both TAK-603 and M-I was found at 1 and 15 mg/kg, and the calculated curves were drawn using constant parameters for the two dosages. These results show that the product inhibition by M-I is one factor responsible for the dose-dependent pharmacokinetics of TAK-603 in rats.  (+info)

High and low molecular weight DNA cleavage in ovarian granulosa cells: characterization and protease modulation in intact cells and in cell-free nuclear autodigestion assays. (5/3077)

To continue elucidation of the biochemical and molecular pathways involved in the induction of apoptosis in granulosa cells (GC) of ovarian follicles destined for atresia, we characterized the occurrence and protease modulation of high and low molecular weight (MW) DNA fragmentation during rat GC death. Atresia of ovarian follicles, occurring either spontaneously in vivo or induced in vitro, was associated with both high MW and internucleosomal (low MW) DNA cleavage. Incubation of follicles in the presence of a putative irreversible and non-competitive inhibitor of caspase-1 (interleukin-1beta-converting enzyme or ICE), sodium aurothiomalate (SAM), completely prevented internucleosomal, but not high MW, DNA cleavage. As reported previously, morphological features of apoptosis (pyknosis, cellular condensation) and atresia (granulosa cell disorganization, oocyte pseudomaturation) remained detectable in SAM-treated follicles. The potential involvement of proteases in endonuclease activation was further analyzed in cell-free assays using nuclei from both GC (which autodigest their DNA) and HeLa cells (HC, which do not autodigest their DNA unless incubated with extracts prepared from other cell types). Crude cytoplasmic extracts prepared from GC induced both high MW and internucleosomal DNA cleavage in HC nuclei. The induction of low, but not high, MW DNA cleavage in HC nuclei by GC extracts was suppressed by pretreatment of the extracts with SAM or with any one of the serine protease inhibitors, dichloroisocoumarin (DCI), N-tosyl-L-leucylchloromethylketone (TLCK) or N-tosyl-L-phenylchloromethylketone (TPCK). Interestingly, SAM and DCI also prevented cation-induced low MW DNA fragmentation in GC nuclei; however, TLCK and TPCK were without effect. Our results support a role for cytoplasmic and nuclear serine proteases in the activation of the endonuclease(s) responsible for internucleosomal DNA cleavage during apoptosis.  (+info)

Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. (6/3077)

OBJECTIVE: To confirm the impression of a better outcome of patients withdrawn from parenteral gold salt therapy compared with those withdrawn from methotrexate. METHODS: Patients with early, active, and erosive RA were randomised for a double blind trial to receive either weekly 15 mg intramuscular methotrexate or 50 mg goldsodiumthiomalate. If the drug had to be withdrawn because of side effects treatment was continued with the other drug in still active disease. Patients with insufficient response were treated with a combination of both drugs. All patients were followed up by an extended clinical and radiographic evaluation. RESULTS: 64 patients each were allocated to methotrexate and gold treatment. After 72 months a complete record was available for 88% of patients. Within the first 36 months 38 patients withdrew from gold treatment (95% because of side effects) and 23 patients withdrew from methotrexate (57% because of side effects). A significant 40% to 70% improvement of all parameters (erythrocyte sedimentation rate, C reactive protein, swollen and tender joints, radiological progression) compared with baseline was observed in patients completing their randomised treatment with gold or methotrexate. The same improvement over three years was seen in patients who withdrew from gold treatment, while patients withdrawing from methotrexate experienced a deterioration of their disease. CONCLUSION: Withdrawals represent the majority of patients in long term drug trials. Patients with early RA stopping gold because of side effects show almost the same sustained improvement as patients continuing gold or methotrexate. Patients withdrawn from methotrexate experience a reactivation of their disease.  (+info)

Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. (7/3077)

BACKGROUND: Sulphasalazine (SSZ) has been reported to cause drug induced systemic lupus erythematosus (SLE), but diagnosis of this complication in the context of rheumatoid arthritis (RA) is difficult. OBJECTIVE: To determine prospectively: (1) if patients become seropositive for antinuclear antibodies (ANA) during prolonged treatment with SSZ without clinical evidence of SLE; (2) if ANA positive patients develop more adverse reactions than ANA negative patients; (3) if drug induced SLE was identified in this cohort. METHODS: 200 patients enrolled in a randomised prospective trial of SSZ and auranofin (AUR) were followed up for five years. Baseline and annual ANA results were collected along with information on drug toxicity and reasons for discontinuation of treatment. RESULTS: Over five years 24 patients stopped taking SSZ and 49 AUR because of side effects. Of the features common to SLE, rash developed in nine SSZ patients and 11 AUR treated patients and mouth ulcers in three and four patients respectively. Six SSZ treated patients and three treated with AUR developed leucopenia, which promptly resolved with drug withdrawal. No adverse event was ascribed to drug induced SLE. Of the 72 SSZ treated patients who were ANA negative or weakly positive at outset, 14 (19%) became strongly ANA positive compared with 11 (14%) of 80 AUR patients. Patients ANA positive at baseline or who became ANA positive were not more likely to develop drug toxicity or to withdraw from treatment than those ANA negative throughout. CONCLUSION: ANA positivity is common in patients with RA, but the presence or development of ANA did not increase the likelihood of withdrawing from treatment. No case of drug induced SLE was seen over five years in this study.  (+info)

In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. (8/3077)

The goal of this study was to determine the efficacy of local IL-1Ra gene therapy by intra-articular plasmid injections on structural changes in the meniscectomy rabbit model of osteoarthritis. A partial meniscectomy of the right knee was performed on the rabbits through a medial parapatellar incision. The rabbits were then divided into four experimental groups. Group 1 received no treatment. Group 2 received three consecutive intra-articular injections at 24-hour intervals of 0.9% saline containing a lipid, gammaAP-DLRIE/DOPE, and a DNA plasmid, VR1012. Group 3 received three consecutive injections of saline containing 1000 microg of canine IL-1Ra plasmid and lipid. The injections were given starting 4 weeks post-surgery. Rabbits from Group 1 were killed 4 weeks post-surgery, and all other rabbits 8 weeks post-surgery. The severity of macroscopic and microscopic changes on cartilage on the medial and femoral condyles and tibial plateaus and synovium were graded separately. Specimens were also processed for immunohistochemical staining using a rabbit polyclonal antibody against canine IL-1Ra. The level of canine IL-1Ra in synovial fluid was determined using enzyme-linked immunosorbent assay. The presence of the DNA plasmid in the synovium was tested by polymerase chain reaction. A significant reduction in the width of osteophytes and size of macroscopic lesions (P < 0.04) was observed, and was dependent on the amount of IL-1Ra plasmid injected. A significant reduction was also noted in the severity of histologic cartilage lesions (P < 0.01) in the group that received the highest dosage (1000 microg) of IL-1Ra plasmid. IL-1Ra was detected in synovial fluid by enzyme-linked immunosorbent assay and by immunohistochemical staining in the synovium and cartilage of rabbits that received injections containing the IL-1Ra plasmid. Polymerase chain reaction analysis of synovial DNA revealed the presence of the cloned cDNA dog IL-1Ra up to 4 weeks after the first intra-articular injection. This study demonstrates that direct in vivo transfer of the IL-1Ra gene into osteoarthritis knee cells using intra-articular injections of a plasmid vector and lipids can significantly reduce the progression of experimental osteoarthritis. This avenue may therefore represent a promising future treatment for osteoarthritis.  (+info)

*Sodium aurothiomalate

ISBN 978-0-9805790-9-3. Berners-Price, SJ; Filipovska, A (September 2011). "Gold compounds as therapeutic agents for human ... is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Along with an orally-administered gold salt, ...

*Disease-modifying antirheumatic drug

The term is often used in contrast to nonsteroidal anti-inflammatory drug (which refers to agents that treat the inflammation ... "disease-modifying antirheumatic drug" at Dorland's Medical Dictionary "Disease modifying antirheumatic drugs (DMARDs)". " ... Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid ... Nandi P, Kingsley GH, Scott DL (May 2008). "Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid ...

*Oxycinchophen

... is an antirheumatic agent. Iversen, M.; Munck, J.; Schourup, K. (1953). "On the toxicity of 3-hydroxy-2- ...

*Aminopropionitrile

It is an antirheumatic agent in veterinary medicine. It has attracted interest as an anticancer agent. Aminopropionitrile is ...

*Bucillamine

... is an antirheumatic agent developed from tiopronin. It is mainly used in Japan and Korea. Activity is mediated by ...

*Aurotioprol

... is a gold salt used as an antirheumatic agent. Perrier, P.; Raffoux, C.; Thomas, P.; Tamisier, J. N.; Busson, M.; ... levamisole and D-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis--a long-term follow-up ...

*Auranofin

... is a gold complex classified by the World Health Organization as an antirheumatic agent. It has the brand name ... the protozoan agent of human amebiasis. Assays of thioredoxin reductase and transcriptional profiling suggest that the effect ...

*Juvenile idiopathic arthritis

Will administration of omega-3 unsaturated fatty acids reduce the use of nonsteroidal antirheumatic agents in children with ... Methotrexate, a disease-modifying antirheumatic drug (DMARD) is a powerful drug which helps suppress joint inflammation in the ...

*Iguratimod

Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K (2002). "An anti-rheumatic agent T-614 inhibits NF-kappaB activation in ... June 29, 2012). "Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan" (Press release ... A novel disease modifying anti-rheumatic drug". Rheumatology Reports. 1 (1). Lu, Liang-jing; Teng, Jia-lin; Bao, Chun-de; Han, ...

*Mepacrine

The main uses of mepacrine are as an antiprotozoal, antirheumatic and an intrapleural sclerosing agent. Antiprotozoal use ... Agents Chemother. 55 (5): 1827-1830. doi:10.1128/aac.01296-10. PMC 3088196 . PMID 21383088. Canete R, Escobedo AA, Gonzalez ME ... As an intrapleural sclerosing agent, it is used as pneumothorax prophylaxis in patients at high risk of recurrence, e.g., ... "quinacrine" at Dorland's Medical Dictionary Doh-Ura K, Iwaki T, Caughey B (May 2000). "Lysosomotropic Agents and Cysteine ...

*List of MeSH codes (D16)

... antirheumatic agents MeSH D27.505.954.329.030 --- anti-inflammatory agents, non-steroidal MeSH D27.505.954.329.337 --- gout ... anti-allergic agents MeSH D27.505.954.122 --- anti-infective agents MeSH D27.505.954.122.085 --- anti-bacterial agents MeSH ... antiviral agents MeSH D27.505.954.122.388.077 --- anti-retroviral agents MeSH D27.505.954.122.388.077.088 --- anti-hiv agents ... renal agents MeSH D27.505.954.613.056 --- anti-infective agents, urinary MeSH D27.505.954.613.860 --- uricosuric agents MeSH ...

*List of ICD-9 codes 800-999: injury and poisoning

Poisoning by agents primarily affecting blood constituents (965) Poisoning by analgesics, antipyretics, and antirheumatics (966 ... Poisoning by agents primarily acting on the smooth and skeletal muscles and respiratory system (976) Poisoning by agents ... Poisoning by agents primarily affecting the cardiovascular system (973) Poisoning by agents primarily affecting the ... Poisoning by other specified psychotropic agents (969.9) Poisoning by unspecified psychotropic agent (970) Poisoning by central ...

*Immunodeficiency

Prognosis of acquired immune deficiencies depends on avoiding or treating the causative agent or condition (like AIDS). ... disease-modifying antirheumatic drugs, immunosuppressive drugs after organ transplants, glucocorticoids) and environmental ... can result from various immunosuppressive agents, for example, malnutrition, aging, particular medications (e.g., chemotherapy ...

*Anakinra

"Anti-Interleukin-1 Agents in Adult Onset Still's Disease". Hindawi. 2012-02-07. Retrieved 2012-10-13. "New type of drug helpful ... Anakinra is not considered a 'disease-modifying antirheumatic drug' (DMARD) but rather a 'biological response modifier' (BRM) ... Anakinra should not be used in combination with anti-TNF agents such as etanercept (Enbrel), infliximab (Remicade) or ... A meeting of experts on Schnitzler's syndrome concluded that "Interleukin-1-neutralizing agents such as anakinra are clearly ...

*List of ICD-9 codes E and V codes: external causes of injury and supplemental classification

Primarily systemic agents causing adverse effects in therapeutic use (E934) Agents primarily affecting blood constituents ... Accidental poisoning by analgesics antipyretics and antirheumatics (E851) Accidental poisoning by barbiturates (E852) ... Agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use (E943) Agents primarily ... Agents primarily acting on the smooth and skeletal muscles and respiratory system causing adverse effects in therapeutic use ( ...

*Rheumatology

Biologic agent Rituximab (Anti-B-Cell Therapy) is now licensed for use in refractory Rheumatoid Arthritis. Physiotherapy is ... Disease-Modifying Anti-Rheumatic Drugs), monoclonal antibodies, such as infliximab and adalimumab, and the soluble TNF receptor ... One of the major changes in modern rheumatology is the development of new drugs called biologics, or disease modifying agents, ...

*Intermittent hydrarthrosis

Where this condition has been correctly diagnosed, various anti-rheumatic drugs as well as colchicine may be trialled to find ... achieved using intra-articular agents (chemical or radioactive) can provide good results, with efficacy reported for at least 1 ... Low-dose colchicine (and some other 'anti-rheumatic' therapies e.g. hydroxychloroquine) have been used with some success. (Use ...

*Penicillamine

It is used as a chelating agent: In Wilson's disease, a rare genetic disorder of copper metabolism, penicillamine treatment ... Penicillamine can be used as a disease-modifying antirheumatic drug (DMARD) to treat severe active rheumatoid arthritis in ... although it is rarely used today due to availability of TNF inhibitors and other agents, such as tocilizumab and tofacitinib. ...

*Cyclophosphamide

In 1959 it became the eighth cytotoxic anticancer agent to be approved by the FDA. The abbreviation CP is common, although ... it remains an important treatment for life-threatening autoimmune diseases where disease-modifying antirheumatic drugs (DMARDs ... The main use of cyclophosphamide is with other chemotherapy agents in the treatment of lymphomas, some forms of brain cancer, ... Like other alkylating agents, cyclophosphamide is teratogenic and contraindicated in pregnant women (pregnancy category D) ...

*Rheumatoid arthritis

Biological agents should generally only be used if methotrexate and other conventional agents are not effective after a trial ... Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the ... The most commonly used agent is methotrexate with other frequently used agents including sulfasalazine and leflunomide. Sodium ... No infectious agent has been consistently linked with RA and there is no evidence of disease clustering to indicate its ...

*Anil Pareek

... insulin sensitizing agent and lipid lowering agent for treatment / prophylaxis of non-alcoholic fatty liver disease. Indian ... Patentee for a novel pharmaceutical composition of statin with disease modifying anti-rheumatic drug vide patent no 206561 ...

*Tenidap

Rationally designed multitarget agents against inflammation and pain. Curr Med Chem. 2013;20(13):1783-99. PMID 23410172 PMC ... a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: A 24-week analysis of a 1-year clinical ...

*Azathioprine

People who have previously been treated with an alkylating agent may have an excessive risk of cancers if treated with ... Being a disease-modifying antirheumatic drug (DMARD), azathioprine has been used for the management of the signs and symptoms ... It is also an important therapy and steroid-sparing agent for inflammatory bowel disease (such as Crohn's disease and ... agent. It was shown to be very effective in eczema and atopic dermatitis in researches, even though it is not commonly used. ...

*Sodium aurothiosulfate

Like several other gold compounds, this species is used as an antirheumatic.The first placebo-controlled trial was probably ... doi:10.1016/S1386-1425(97)83024-7. Shaw, III, C. F. (1999). "Gold-Based Therapeutic Agents". Chemical Reviews. 99 (9): 2589-600 ...

*Baliospermum montanum

Seed is rubefacient, stimulant, purgative, and antidote for snakebite and its oil is antirheumatic. Leaf is antiasthmatic and ... Potential anticancer agents. VIII. Constituents of Baliospermum montanum (Euphorbiaceae). Planta med., 33:128.. ...

*Drug class

Similarly, one might argue that the class of disease-modifying anti-rheumatic drugs (DMARD) is composed by one element (" ... not all triglyceride lowering agents are PPAR agonists, and not all drugs that are used to treat atherosclerosis are ... Nonsteroidal anti-inflammatory drug (NSAID) Disease-modifying antirheumatic drug (DMARD) Biopharmaceutics Classification System ... "disease-modifying") that albeit vaguely designates a mechanism of action, and one element ("anti-rheumatic drug") that ...

*ICD-10 Chapter XIX: Injury, poisoning and certain other consequences of external causes

Poisoning by agents primarily affecting the gastrointestinal system (T48) Poisoning by agents primarily acting on smooth and ... Antirheumatics, not elsewhere classified (T40) Poisoning by narcotics and psychodysleptics (hallucinogens) (T40.0) Opium (T40.1 ... Poisoning by primarily systemic and haematological agents, not elsewhere classified (T46) Poisoning by agents primarily ... antipyretics and antirheumatics (T39.0) Salicylates (T39.1) 4-Aminophenol derivatives (T39.2) Pyrazolone derivatives (T39.3) ...
OBJECTIVES To investigate and compare the risk for malignancy in rheumatoid arthritis (RA) patients treated with biologics in Japan to the general population. METHODS Data for 14,440 patients from 335 institutions who were given infliximab, etanercept, adalimumab, golimumab, tocilizumab, or abatacept were retrieved from the SafEty of biologics in Clinical Use in Japanese patients with RhEumatoid arthritis (SECURE) database. RESULTS We identified 333 incidents of malignancies in 320 patients during 49,320 patient-years (PY). The age- and sex-standardized incidence rate (ASR) (95% confidence interval [CI]) for overall malignancy of the SECURE cohort was 313.9/10(5) PY (271.4-361.3), and the standardized incidence rate ratio (SIR) (95% CI) was 0.745 (0.667-0.826). The ASR was decreased compared to the estimated incidence rate of malignancies in the Japanese general population (462.4/10(5) PY). The SIRs for site-specific nonhematopoietic malignancies of the SECURE cohort were not significantly elevated
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 57, No. 3, April 15, 2007, pp 440 - 447 DOI 10.1002/art.22619 © 2007, American College of Rheumatology ORIGINAL ARTICLE Evaluation of the Preliminary Definitions of Minimal Disease Activity and Remission in an Early Seropositive Rheumatoid Arthritis Cohort DINESH KHANNA,1 MYUNGSHIN OH,2 DANIEL E. FURST,2 VEENA RANGANATH,2 RICHARD H. GOLD,2 JOHN T. SHARP,3 GRACE S. PARK,2 EDWARD C. KEYSTONE,4 AND HAROLD E. PAULUS,2 FOR THE WESTERN CONSORTIUM OF PRACTICING RHEUMATOLOGISTS Objective. To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA). Methods. The cohort comprised disease-modifying antirheumatic drug (DMARD)-naive patients with early seropositive active RA (n ⴝ 200) treated with traditional DMARDs in the prebiologic era. MDA definitions included Disease Activity Score in 28 joints (DAS28) ,2.85, or achieving 5 of 7 World Health Organization ...
Results Fifty-two percent (n=424) of the 823 patients remained on the first bDMARD and were followed for at least 360 days. Forty-three percent of them (205) were adherent to all prescribed anti-rheumatic medication. CsDMARDs were prescribed to 372 patients of which 53% (196) were adherent while 5% (20) claimed no cdDMARD at all. Methotrexate was the most common csDMARD and was prescribed to 281 patients. The proportions of patients adherent to methotrexate and patients who claimed no methotrexate at all were 60% (170) and 9% (26), respectively. Self-injectable bDMARDs were prescribed to 319 of which 59% (187) were adherent and 8% (25) did not claim any of the prescribed bDMARD. Mean PDC for csDMARDs, methotrexate and self-injectable bDMARDs were 73%, 74% and 74%, respectively. ...
Results Fifty-one full papers, and 57 abstracts were identified. The randomised controlled trials (RCT) confirmed the efficacy of bDMARD+conventional synthetic DMARDs (csDMARDs) versus csDMARDs alone (level 1B evidence). There was some additional evidence for the use of bDMARD monotherapy, however bDMARD and MTX combination therapy for all bDMARD classes was more efficacious (1B). Clinical and radiographic responses were high with treat-to-target strategies. Earlier improvement in signs and symptoms were seen with more intensive initial treatment strategies, but outcomes were similar upon addition of bDMARDs in patients with insufficient response to MTX. In general, radiographic progression was lower with bDMARD use, mainly due to initial treatment effects. Although patients may achieve bDMARD- and drug-free remission, maintenance of clinical responses was higher with bDMARD continuation (1B), but bDMARD dose reduction could be applied (1B). There was still no RCT data for bDMARD ...
INTRODUCTION Disease-modifying anti-rheumatic drugs (DMARDs) currently form the mainstay of treatment of rheumatoid arthritis (RA). We aimed to evaluate the retention rates of therapeutic segments of DMARDs in patients with RA. METHODS This was a cross-sectional study of RA patients with at least one year of follow-up. A therapeutic segment is said to begin when one DMARD combination is instituted and it ends with a subsequent change. The disability index for each patient was calculated using a modified health assessment questionnaire. Retention rates were calculated using the Kaplan Meier survival analysis. RESULTS 375 DMARD courses in 102 patients were analysed. 99 courses were being continued at the time of the study and hence were censored for the purposes of analysis. The respective median (interquartile range [IQR]) retention period for segments containing methotrexate (MTX), sulfasalazine, hydroxychloroquine and leflunomide was 28 (15-45), 12 (3-20), 18 (9-24), 15 (4-32) months. The log
This post marketing observational study will be conducted in cross-sectional, non-interventional, multi-center format in Turkey. As this is a post marketing observational study, Abbott is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.. Subjects will be recruited from rheumatology outpatient clinics of university hospitals and/or private offices.. Patients diagnosed with rheumatoid arthritis who had received at least one disease-modifying anti-rheumatic drug, who are already employed at a paid work and able to provide disease history data will be included.. Patient data will be collected with a single visit. During the single visit, all required demographic and clinical data will be recorded on the case report forms by the investigators and every subject will be asked to fill out the Work Productivity and Activity Impairment ...
This is a randomized (treatment assigned by chance, like flipping a coin), multicenter, double-blind (neither physician nor patient will know the treatment the patient receives), parallel-group (each group of patients will be treated at the same time) study. JNJ-40346527 will be compared to a placebo, which is an inactive substance used to test whether a drug has a real effect. Patients will receive study medication for 12 weeks and will continue their permitted, stable DMARD therapy (methotrexate [MTX], sulfasalazine [SSZ], and/or hydroxychloroquine [HCQ]) through Week 12. A follow-up visit will occur 4 weeks after dosing is complete. The maximum length of patient participation will be 22 weeks, including a 6-week screening period. Other study visits will occur during the study, and patient safety will be monitored ...
Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid arthritis to slow down disease progression. The term is often used in contrast to nonsteroidal anti-inflammatory drug (which refers to agents that treat the inflammation but not the underlying cause) and steroids (which blunt the immune response but are insufficient to slow down the progression of the disease). The term "antirheumatic" can be used in similar contexts, but without making a claim about an effect on the course. Other terms that have historically been used to refer to the same group of drugs are "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs). Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name) the term has come to pertain to many other diseases, such as Crohns disease, lupus erythematosus (SLE), Sjögren syndrome, immune thrombocytopenic purpura (ITP), myasthenia gravis, ...
Title: Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. VOLUME: 7 ISSUE: 4. Author(s):Kunihiro Yamaoka and Yoshiya Tanaka. Affiliation:The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.. Keywords:Rheumatoid arthritis, Janus kinase, Kinase inhibitor, tacositinib, tofacitinib. Abstract: Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as Tumor necrosis factor (TNF), Interleukin-6 (IL-6) and CTLA-4 has become a major focus in the field. Biologic agents are generally more effective than traditional disease-modifying antirheumatic drugs (DMARDs) when combined with MTX. However, not only about 30% of patients respond poorly to treatment but also the parenteral mode of administration and expenses are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy on ...
Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis ...
Risk of solid cancer in patients exposed to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis". Mercer, L. et al. Ann Rheum Dis , published on line first 31 March 2014. Authors compared the risk of solid cancer in patients with rheumatoid arthritis treated with TNF inhibitors to that in patients treated with non-biologic (synthetic) disease modifying anti-rheumatic drugs (sDMARDs).. British Society for Rheumatology Biologic Register was established in 2001 to monitor for long-term safety of TNF inhibitors. Patients from that register were followed via record linkage with the national cancer registries until first solid cancer, death, for 5 years or until 2011. Solid cancer rates in 11767 patients without prior cancer treated with TNF inhibitor were compared to those in 3249 patients without prior cancer treated with sDMARDs (ex., methotrexate, sulfasalazine, leflunomide).. 81 cancers per 10000 patient-years were ...
Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such as rituximab; however, there are limited data available to help physicians decide between these 2 strategies. The objective of this analysis was to examine the effectiveness and safety of rituximab versus a subsequent anti-TNF agent in anti-TNF-experienced patients with RA using clinical practice data from the Corrona registry. Rituximab-naive patients from the Corrona registry with prior exposure to ≥1 anti-TNF agent who initiated rituximab or anti-TNF agents (2/28/2006-10/31/2012) were included. Two cohorts were analyzed: the trimmed population (excluding patients who fell outside the propensity score distribution overlap) and the stratified-matched population (stratified by 1 vs ≥2 anti-TNF agents, then matched based on propensity score). The primary effectiveness outcome was
Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti-TNF)agent treatment can switch to either a subsequent anti-TNF agent or a biologic with an alternative mechanism of action, such as rituximab; however, there are limited data available to help physicians decide between these 2 strategies. The objective of this analysis was to examine the effectiveness and safety of rituximab versus a subsequent anti-TNF agent in anti-TNF-experienced patients with RA using clinical practice data from the Corrona registry. Rituximab-naive patients from the Corrona registry with prior exposure to ≥1 anti-TNF agent who initiated rituximab or anti-TNF agents (2/28/2006-10/31/2012) were included. Two cohorts were analyzed: the trimmed population (excluding patients who fell outside the propensity score distribution overlap) and the stratified-matched population (stratified by 1 vs ≥2 anti-TNF agents, then matched based on propensity score). The primary effectiveness outcome was
BACKGROUND: Tumour necrosis factor (TNF) is known to increase the concentrations of interleukin (IL) 6 and C reactive protein (CRP) and to induce proatherogenic changes in the lipid profile and may increase the cardiovascular risk of patients with rheumatoid arthritis (RA) and other inflammatory disorders. OBJECTIVE: To assess whether anti-TNF therapy modifies the cardiovascular risk profile in patients with RA. METHODS: The lipoprotein spectrum and the inflammation markers CRP and IL6 were investigated in 33 patients with RA treated with human anti-TNF monoclonal antibodies (D2E7, adalimumab, Humira) and 13 patients with RA given placebo, before and after 2 weeks treatment. RESULTS: In the anti-TNF treated group, the mean (SD) concentrations of HDL-cholesterol were significantly higher after 2 weeks treatment (0.86 (0.30) mmol/l v 0.98 (0.33) mmol/l, p,0.01), whereas LDL and triglyceride levels were not significantly changed. Additionally, a significant decrease in CRP (86.1 (54.4) mg/l v ...
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
OBJECTIVE: To study the risk of a second malignant neoplasm (SMN) and mortality in patients with rheumatoid arthritis (RA) with a history of a primary cancer diagnosis and treated with biological disease-modifying antirheumatic drugs (bDMARD). METHODS: Among patients with RA (n=15 286) registered in the DANBIO Register during 2000-2011, 1678 had a primary cancer according to the Danish Cancer Registry. HRs for SMN and death were calculated. RESULTS: During follow-up there were 279 patients with RA contributing person-years to the bDMARDs use before their primary cancer diagnosis, 220 to the only after, 92 to the both before and after, while 1203 patients with RA contributed to the non-use strata ...
Methotrexate is a commonly-used DMARD which, like the others, reduces the activity of the immune system, resulting in a decrease in the inflammation which drives rheumatological conditions. This helps to prevent underlying joint damage caused by on-going inflammation, as well as easing the symptoms of pain and swelling associated with these conditions. Methotrexate is usually prescribed for people with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis and vasculitis. It is usually taken once a week in tablet form, although injections are also available. You will need a blood test and a chest X-ray before starting the drug, and the blood tests will continue at regular intervals when taking methotrexate. For more information visit the Arthritis Research UK website.. ...
While still in Florida, they picked up another hitchhiker, Dennis Weaver, who rode with them to Atlanta, where he was let out about 11 pm? Attorney longest dinex uk General Eric Holder authorized a study of racial disparities in the federal death penalty during his tenure as Deputy Attorney General during the Clinton Administration? Similarly, ceftin tablets price excluding patients in whom insomnia developed with fluoxetine or desipramine did not alter the results. Im a 24-year-old male and I got some 0025% Retin-A (Ortho/ johnson&johnson brand) online? I went to the referral and they did thorough research into all my lab tests and came back stating I did not have kidney disease? Only a handful of girls met all the criteria in any given season. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: Part II Safety! Three deltasone 10 tablets price floatingly of these states ...
Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 2009; 36: 2397-402 ...
In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA.
For a complex, progressive, chronic disease such as rheumatoid arthritis, the timing of intervention is critical. In the past, the recommended treatment approach was slow and steady, referred to as "the pyramid"-ie, a base of physical therapy and non-pharmacological interventions, followed by conservative treatment with non-steroidal anti-inflammatory drugs, then glucocorticoid steroids and, finally, administration of a conventional disease-modifying antirheumatic drug (DMARD). This concept is now inverted. Intensive intervention, initiated earlier, with conventional and biological DMARDs is increasingly recommended ...
Follow-up there was a time categorized on the person-day foundation intended for treatment coverage. Several teams of medicines appealing have been the following: anti-tumor necrosis factor (TNF) biologics (adalimumab, etanercept, infliximab, certolizumab, as well as golimumab), non-TNF biologics (abatacept along with rituximab), nonbiologic immunosuppressive drugs (or perhaps disease-modifying antirheumatic drug treatments [DMARDs]) (methotrexate, hydroxycholoroquine, sulfasalazine, azathioprine, leflunomide, cyclosporine, and 6-mercaptopurine), and also oral glucocorticoids. Experience of biologics and also nonbiologic DMARDs was firm depending on prescribed time along with days of supply and, with regard to infusions, the particular encouraged dosing intervals. For example, the patient who gotten an infliximab infusion was deemed exposed to infliximab for the next Fifty six days and nights from the infusion day. As the exact every day dose associated with mouth glucocorticoids is actually ...
The goal of this research was to compare the demographics, clinical characteristics and treatment patterns for newly diagnosed multiple sclerosis (MS) patients in a commercial managed care population who received disease-modifying drug (DMD) therapy
Objective To determine whether intensive combinations of synthetic disease modifying drugs can achieve similar clinical benefits at lower costs to high cost biologics such as tumour necrosis factor inhibitors in patients with active rheumatoid arthritis resistant to initial methotrexate and other synthetic disease modifying drugs.. Design Open label pragmatic randomised multicentre two arm non-inferiority trial over 12 months.. Setting 24 rheumatology clinics in England.. Participants Patients with rheumatoid arthritis who were eligible for treatment with tumour necrosis factor inhibitors according to current English guidance were randomised to either the tumour necrosis factor inhibitor strategy or the combined disease modifying drug strategy.. Interventions Biologic strategy: start tumour necrosis factor inhibitor; second biologic in six month for non-responders. Alternative strategy: start combination of disease modifying drugs; start tumour necrosis factor inhibitors after six months in ...
Abatacept(Orencia) generic is a synthetic protein, prescribed for adult with moderate to severe rheumatoid arthritis including patients who have not responded to DMARDs (disease-modifying anti-rheumatic drugs), and juvenile idiopathic arthritis. It blocks the activity of T-cells, which causes swelling and joint damage in people with arthritis condition.
Background: Calprotectin (S100A8/A9 or MRP8/14) and S100A12 (leukocyte-derived proteins), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) are markers of inflammation and angiogenesis. Ultrasound (US) is sensitive for detection of greyscale synovitis and power Doppler (PD) vascularization. The objective of the present study was to explore the associations between calprotectin, S100A12, IL-6, VEGF, erythrocyte sedimentation rate, C-reactive protein and a comprehensive US assessment in patients with rheumatoid arthritis (RA) starting biologic disease-modifying anti-rheumatic drug (bDMARD) treatment.. Methods: A total of 141 patients with RA were assessed by US, clinical examination and biomarker levels at baseline and at 1, 2, 3, 6 and 12 months after initiation of bDMARDs. US assessment of 36 joints and 4 tendon sheaths were scored semi-quantitatively (0-3 scale). European League Against Rheumatism (EULAR) response was calculated. Statistical assessments performed to explore the ...
Methods PB Treg cells, defined as the CD4+CD25highCD127low/- population, were examined by flow cytometry in 48 patients with RA, including 13 who had never received disease-modifying antirheumatic drugs (DMARD), 19 with active disease who were receiving (n = 14) or had received (n = 5) DMARD, and 16 receiving DMARD whose disease was in remission. The clinical disease activity of the patients was defined by the 28-joint Disease Activity Score (DAS28). The association of DAS28, C-reactive protein (CRP), or erythrocyte sedimentation rate (ESR) with the frequency of PB Treg cells was examined. ...
Safety of TNF inhibitors in adolescents and children Lauren Keyser McCluggageClinical Pharmacy, Philadelphia College of Pharmacy, Philadelphia, PA, USAAbstract: This article describes the use of tumor necrosis factor (TNF) inhibitors in children, reviews the pharmacology of these agents, and reviews and summarizes the current safety information available for etanercept, adalimumab, and infliximab. TNF inhibitors are being used for a variety of indications in children including Crohns disease and juvenile idiopathic arthritis. However, the full safety profile of these agents is still not known. In adult patients, TNF inhibitors have demonstrated a variety of adverse effects including increased risk of infection, malignancy, demyelinating disorders, and reactivation of latent diseases. In children the rate of adverse effects is harder to elucidate due to the limited number of patients in clinical trials and limited case reports. However, based on the data available, TNF inhibitors have been implicated in
Results. There were 528 patients with sJIA enrolled in the registry (2010-2013). There were 435 patients who had a complete dataset; of these, 372 met the International League of Associations for Rheumatology criteria and were included in the analysis. At enrollment, median disease duration and joint count were 3.7 years and 0, respectively; 16.4% had a rash and 6.7% had a fever. Twenty-six percent were taking interleukin 1 (IL-1) inhibitors and 29% glucocorticoids. Disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors use decreased, while IL-6 inhibitor use increased between 2010 and 2013. African American patients had worse joint counts (p = 0.003), functional status (p = 0.01), and physicians global assessment (p = 0.008). Of the 255 subjects with , 2 years of disease duration, 56% had no arthritis or systemic symptoms, while 32% had persistent arthritis only. ...
To analyze the results of using methotrexate MT in the treatment of psoriasis psoriazis metodzhekt psoriatic arthritis PsA. The mechanism of action of MT, the historical aspects of its use in the treatment of psoriasis and PsA, and the data of clinical trials of the efficacy and safety of the drug are considered.. MT therapy is shown to cause a high rate of adverse reactions, which requires measures to prevent and treat psoriazis metodzhekt events. MT has been found to be frequently used in different combinations, including with other disease-modifying antirheumatic drugs sulfasalazineprednisolone, and biological agents, such as tumor necrosis factor inhibitors. In accordance psoriazis metodzhekt the European S3-guidelines S3 on the systemic treatment of psoriasis, MT In terms of the present-day views, the indications for immunosuppressive therapy for PsA may be expanded it should be initiated in the early stage of the disease, psoriazis metodzhekt in its severe forms, until there are ...
OBJECTIVE: To evaluate whether use of comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) influences the retention of tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA). METHODS: Patients with SpA from the Rheumatic Diseases Portuguese Register who started treatment with their first TNFi between 2001 and 2014 were included in this study. Cox regression analysis was used to estimate the effect of comedication with csDMARDs on TNFi retention in 2 types of models: a model in which baseline (time-fixed) variables were included, and a second model incorporating time-varying variables, including sociodemographic features, measures of disease activity, measures of physical function, and cotreatment with other drugs (nonsteroidal antiinflammatory drugs and oral steroids ...
Biologists have come up with a drug known as "Disease-modifying Anti-rheumatic Drug." It is commonly referred to as DMARD. This drug is very effective in reducing bone and joint damage as well as treating the symptoms of Rheumatoid Arthritis. This medication can also be used alongside glucocorticoids and NSAIDs. Other types of analgesics or anti-inflammatories are not required when taking this medication.. DMARDS work by targeting the immune system. However, you need to be extra vigilant when using these drugs as they may weaken your immune system. This calls for regular blood tests among the patients using this drug .this would ensure that the drug does not hurt certain organs or the blood cells. The organs affected by this drug include the kidneys, lungs and the liver.. These are a special type of the ...
OBJECTIVE: To evaluate the longterm effectiveness of disease modifying antirheumatic drugs (DMARD) in an inception cohort of patients with rheumatoid arthritis (RA) seen by rheumatologists. METHODS: We performed a retrospective audit of the records o
As my dear housemates surrounded me with love that evening, I saw a glimmer of the old me while they filled me with acknowledgement and appreciation for who I BE. Overall Case Analysis: Kate had, essentially, three chronic illnesses: menstrual difficulties, depression, and asthma. But, the participants did have decreases in morning stiffness and pain plus some even saw improvement inside their ability to work. Prednisone is really a type of corticosteroid drug that has multiple uses and purposes because it can bring relief to many people ailments. But I hadnt expected the drug that has been keeping her alive ahead with such an extended, unpleasant set of noticeable negative effects:. Thankfully the clinic has the capacity to get me large discounts of $10 for the blood work. Once she was inside the room and coherent, she complained of the constant itch. These drugs would be the disease-modifying anti-rheumatic drugs (DMARDs); we were holding once reserved for that later stages of RA, along with ...
Health, ...Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective...Steroids are commonly used in Crohns disease but can stunt growth an...This study is the largest double-blind study of an anti-TNF agent in c...The promising results of treatment with adalimumab are extremely encou...,Adalimumab,is,a,promising,therapy,for,children,with,Crohns,disease,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The primary endpoint of the study was the proportion of patients meeting the ACR 20 criteria, a way of measuring patient improvement using American College of Rheumatology (ACR) guidelines. By achieving ACR 20, a patient has at least a 20 percent improvement in multiple measures of disease activity. In this study of people with active rheumatoid arthritis despite treatment with etanercept, 85 people received a once-monthly infusion of a 2 milligram per kilogram (mg/kg) dose of CTLA4Ig and twice-weekly injections of etanercept. Another 36 people studied received a placebo in addition to the twice-weekly etanercept injections ...
To ask the Secretary of State for Health (1) if the health service across England will be ready to implement the prescription-plus-monitoring scheme for beta interferons from its start date of 6 May; [55317] (2) how many people he estimates will receive beta interferon under the prescription-plus monitoring scheme; [55307] (3) what progress has been made on the prescription- plus monitoring scheme for disease-modifying drugs for MS; [55308] (4) how long he estimates it will take for all people who may benefit from beta interferons to have been assessed by a neurologist for the prescription-plus- monitoring scheme; [55309] (5) when he estimates that all people who may benefit from beta interferons will be in receipt of them; [55310] 15 May 2002 : Column 742W. (6) if he will list the centres that will be authorised to prescribe beta interferons through his Departments prescription-plus-monitoring scheme; [55311] (7) what predictions each centre authorised to prescribe disease-modifying drugs for ...
In conclusion, TNF inhibitors are risk category B drugs in pregnancy that, based on our evaluation of the available literature, do not pose high risk of teratogenicity or intrauterine death. A small magnitude increase in risk cannot be ruled out given the paucity of data on the subject. Although TNF inhibitor use may be associated with a higher rate of preterm delivery, this may in fact be due to the active underlying disease. The decision to use these drugs should, therefore, be made on a case-by-case basis, taking into account severity of disease and the potential benefits and harms of using immunomodulators versus contending with the inherent risks to the pregnancy caused by the inflammatory disease. Questions regarding activity of the disease, the potential for organ- or life-threatening complications, and available alternative medications must be addressed when a patient desires to become pregnant or has become pregnant while taking a TNF inhibitor. If the disease is quiescent or can be ...
Results The number of current medication was found to weakly correlate with DAS-28 (r=0.386), and negatively with intake of ethanol (r=-0.277). When users of biological disease modulating anti-rheumatic drugs (bDMARDs) were compared with non-users, the biologics-taking patients tended to have higher intake of total energy and carbohydrates than non-users. Use of oral corticosteroids, nor other anti-rheumatic DMARDs, did not significantly impact the total energy or carbo intake in RA patients. Sodium intake did not correlate with the disease status or the number of medications. ...
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohns disease ...
Methods Power calculations were conducted based on a Poisson distribution to estimate the minimum PY of exposure needed to have 90% probability that the lower bound of the confidence interval (CI) for tofacitinib minus TNFi will be ,1, for true tofacitinib rates of 1.2×, 1.5× or 2.0× the comparator rates. Rates of events for TNFi were derived from sources (i.e., published clinical trials and observational studies) intended to optimise similarity to the tofacitinib clinical trial database in term of baseline characteristics, study duration and average patient follow-up time. ...
GlaxoSmithKlines IkappaB kinase 2 (IKK-2) inhibitor, TCPA-1 as a potential next generation disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis : Pharmaceutical feature | PharmiWeb.com
Arava (Leflunomide) is an anti-inflammatory medication known as a disease-modifying antirheumatic drug (DMARD) because it not only decreases the pain and swelling of arthritis but also can decrease...
2002년 AECG 분류 기준에 포함되었던 주관적인 건조 증상은 새로운 분류 기준에서 제외되었다. 그러나 AECG 분류 기준의 항목에 있는 건조 증상에 관한 질문을 이용하여 안구건조나 구강 건조 중 하나만 동반되어 있는 환자에도 2016년 ACR/EULAR 분류 기준을 적용할 수 있게 되었다. 또한 2016년 ACR/EULAR 분류 기준에서는 쇼그렌증후군이 전신 질환임을 고려하여, 건조 증상이 없는 환자에서도 EULAR Sjögrens Syndrome Disease Activity Index의 도메인 중에서 한 개 이상이라도 양성이 확인되면 쇼그렌증후군의 분류 기준을 적용할 수 있다. 특히 전신 증상이나 B세포 활성화 지표들(B cell activation markers)은 특히 건조 증상은 거의 없는 젊은 환자들에서 흔하게 발생한다. 2016년 ACR/EULAR 분류 기준이 임상 연구에 포함될 환자를 모집하기 위한 연구 목적으로 만들어진 점을 고려하였을 때, ...
1. Patient is diagnosed and commenced on treatment within three months of symptom 2. Immediate introduction of single or combination disease modifying anti-rheumatic drug 3. Early use of Corticosteroid to obtain restoration of normal joint function 4. Establish a standardised protocol and treat according to the disease activity score 5. Perform disease activity score at each assessment 6. Monthly visits in the first stages of disease until disease activity score has been reduced to less then 2.6 in early disease and 3.2 in established disease 7. Consider biologic therapy early in non-responders and patients with poor prognostic signs ...
Scientists at EPFL and NTU have discovered that combining an anticancer drug with an antirheumatic produces improved effects against tumors. The discovery opens a new path for drug-drug synergy.
The risks of serious infections among patients with rheumatoid arthritis treated with anti-tumor necrosis factor agents were similar to those for patients given other types of biologics, a retrospecti
A striking feature in patients with IPF is the heterogeneity in disease progression, leading some patients to appear stable or to show a slow decline, whereas others decline rapidly with acute exacerbations and rapid deterioration of pulmonary functions [31]. This makes patient care management very challenging, and may have hampered successful development of novel disease-modifying drugs in the past. It is thus not surprising that much effort has been made to identify methods, including biomarkers, for reliable prognosis and to support the appropriate treatment regimens [32].. In this biomarker study, we employed serum samples from the BUILD-3 clinical trial to assess the prognostic capabilities of four previously reported putative IPF biomarkers: MMP-7, FasL, OPN and PICP. To our knowledge, BUILD-3 was the first large-scale phase 3 clinical trial in IPF to include longitudinal sampling for biomarker analysis. In our study, MMP-7 was the only biomarker that showed significantly increased levels ...
If you have a herpes blister on your breast thats close to your nipple or areola, dont nurse from that side until the area has completely cleared up. HSV is part of a group of 8 herpes viruses that can cause human disease. "Humans often perceive infant crying as stress, but for infant animals irritability is a normal component of signaling to parents," the authors wrote. She had gone off of her disease-modifying drug (Rebif) when she learned she was pregnant and she planned to breastfeed for a certain period of time before going back on Rebif. Thus considering the above given points, it can be concluded that breastfeeding is definitely the best option but there is no need to be guilty if you are bottle feeding your baby. There is a 15-45 chance of passing HIV to your baby if neither of you take HIV treatment. This process will lead to a recurrence of symptoms or a more actively contagious state without recognizable symptoms (known as asymptomatic or silent shedding).. However, HSV-1 may also ...
Drug Type Start Stop / Notes Methotrexate 25 mg DMARD 7/12/2008 9/15/2008 Humira TNF Blocker 1/15/2009 8/12/2009 Simponi TNF Blocker 8/12/2009 12/9/2009 Enbrel TNF Blocker 12/9/2009 4/18/2011 Enbrel + 10 mg leflunomide TNF Blocker 4/18/2011 2/1/2012 Orencia + 10 mg leflunomide T-Cell 2/1/2012 10/16/2013 Cimzia + 20 mg leflunomide TNF Blocker 10/16/2013 3/19/2014 Xeljanz +…
Press release - Reports Monitor - Global TNF Inhibitors Market Growth Opportunity and Industry Forecast to 2022 - published on openPR.com
Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting Additional Analyses Further Evaluate Safety and Efficacy of
Treatment with TNF inhibitors was associated with lower rates of cancer than conventional therapies, but opportunistic infections were increased.
Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infec...
The products listed in this website are provided with important information for our Clients like warranty, installation and maintenance instructions, etc. that can easily be downloaded.. For an easy search just type the name or model of the product you are looking for.. If you have any trouble finding the product you are looking for or any information regarding such product, please contact us.. ...
In clinical scientific studies in sufferers with RA, an elevated chance of great bacterial infections has become witnessed with the combination of TNF blockers with anakinra or abatacept, with no additional reward; as a result, use of HUMIRA with abatacept or anakinra is just not advised in people with RA [see WARNINGS AND Safety measures]. The next amount of look at here now great infections has also been observed in patients with RA treated with rituximab who been given subsequent cure having a TNF blocker ...
高い抗原親和性、特異性と安定した品質を兼ね備えたアブカムのウサギ・モノクローナル抗体 RabMAb® ab68160 交差種: Hu 適用: WB,Flow Cyt
DAS.GOLDBERG Nature Spa extends a personal invitation to you. To enjoy relaxing, regenerating treatments. Sensitive hands. And rejuvenating moments.
Do you really want to delete this prezi? Neither you, nor the coeditors you shared it with will be able to recover it again. DeleteCancel ...
TY - JOUR. T1 - A longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. AU - Hamann, Philip D H. AU - Shaddick, Gavin. AU - McHugh, Neil. AU - Hyrich, Kimme. AU - Pauling, John D. PY - 2018/4/30. Y1 - 2018/4/30. N2 - Background: Attainment of remission or low disease activity (LDA) are recommended targets for rheumatoid arthritis (RA) treatment, and associated with improved functional and radiographic long-term outcomes. However, evidence reporting the prevalence of sustained remission/LDA is sparse. This study examines how often sustained remission/LDA occurs, and how this outcome has changed between 2001 and 2013 in patients with RA treated with anti-tumour necrosis factor (TNF) using data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA).Methods: ...
TY - JOUR. T1 - Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. AU - Iervolino, Salvatore. AU - Di Minno, Matteo Nicola Dario. AU - Peluso, Rosario. AU - Lofrano, Mariana. AU - Russolillo, Anna. AU - Di Minno, Giovanni. AU - Scarpa, Raffaele. PY - 2012/3. Y1 - 2012/3. N2 - Objective. To identify predictors of early minimal disease activity in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor-&αλπηα; (TNF-α) antagonists. Methods. In total 146 consecutive patients with PsA eligible for anti-TNF- &αλπηα; therapy were enrolled. At baseline (T0) information about age, sex, PsA subset, disease duration, comorbidities, and treatments was collected. All subjects were tested for metabolic syndrome (MetS) and/or liver steatosis. A clinical and laboratory evaluation was performed at T0 and at 3 months (T3). Changes in all these variables were compared in subjects achieving minimal disease ...
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from a long-term (52-week) phase III trial of OTEZLA, the Companys oral, selective inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs (DMARDs). The data were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.. "Physicians need a variety of options to treat psoriatic arthritis, as treatment is highly individualized and some patients may not be appropriate candidates for biologics or certain systemic therapies," said Alvin Wells, M.D., Ph.D., director, Rheumatology and Immunology Center, Franklin, MN. "These efficacy and safety results suggest that OTEZLA monotherapy has the potential to be used for adults with active psoriatic arthritis in the first-line setting, prior to the initiation of DMARDtherapy, and possibly ...
In part 1 of A Paradigm Shift in Rheumatoid Arthritis Disease Activity, we considered some reasons why better ways of considering RA disease activity are n
In a final appraisal determination, NICE has recommended the biological disease-modifying antirheumatic drug (DMARD) sarilumab (Kevzara) for routine NHS use in the treatment of certain patients with rheumatoid arthritis.. Sarilumab, in combination with methotrexate, is recommended as an option for the treatment of severe active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional DMARDs. Severe disease is defined as a disease activity score (DAS28) of more than 5.1. Sarilumab is also recommended with methotrexate in adults with severe active disease who have responded inadequately to, or who cannot take, other DMARDs, including at least one biological DMARD, and who cannot take rituximab.. NICE adds that sarilumab can be used as monotherapy in patients who cannot take methotrexate because of a contraindication or intolerance. Treatment should be continued only if there is at least a moderate response, as measured using ...
Automatic Prediction of Rheumatoid Arthritis Disease Activity from the Electronic Medical Records The Harvard community has made this article openly available. Please share how this access benefits you.
TY - JOUR. T1 - Cyclosporine and methotrexate for severe rheumatoid arthritis. AU - Schlesinger, Naomi. AU - Huppert, Arthur. AU - Hoch, Susan. AU - Malleson, Peter. AU - Steinberg, Alfred D.. AU - Rosh, Joel. AU - Birnbaum, Audrey H.. AU - Van de Rijn, Matthijs. AU - Kamel, Onsi W.. AU - Storb, Rainer. AU - Thomas, E. Donnall. AU - Tugwell, Peter. AU - Yocum, David. AU - Pincus, Theodore. AU - Wells, George. PY - 1995/12/7. Y1 - 1995/12/7. N2 - To the Editor: Tugwell et al. (July 20 issue)1 found that "patients with severe rheumatoid arthritis and only partial responses to methotrexate had clinically important improvement after combination therapy with cyclosporine and methotrexate." We are concerned about the manner in which the cyclosporine doses were adjusted. No mention of the patients serum cyclosporine levels was made. Determination of serum cyclosporine levels might have allowed a better understanding of the results with respect to therapeutic serum ranges of this medication. The ...
Rheumatoid arthritis (RA) is the most common inflammatory form of arthritis. It is a systemic autoimmune driven process that affects more than 2 million Americans.. While disease-modifying anti-rheumatic drugs (DMARDS) were our stalwarts through the 1980′s and early 1990′s, biologic drugs, specifically TNF inhibitors, have changed our whole way of looking at the treatment of rheumatoid arthritis.. Using these drugs in combination with DMARDS, it has been possible to induce remission in many patients with RA.. TNF inhibitors block the effects of tumor necrosis factor (TNF), a protein messenger that drives the autoimmune process that causes the destructive potential of RA.. There are five TNF inhibitors that have been approved by the FDA. The first is Enbrel. This is a fusion protein with a receptor that binds to circulating TNF in the blood. By acting like a sponge it reduces the signs and symptoms of RA. It is generally best when used in combination with methotrexate. The drug is given by ...
The European Commission (EC) has approved Pfizers Xeljanz (tofacitinib citrate) oral tablets to treat moderate-to-severe active rheumatoid arthritis (RA) in adult patients in the European Union (EU).. The 5mg twice-daily (BID) tablets have been approved in combination with methotrexate (MTX) for patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).. Xeljanz belongs to a new class of therapies called Janus kinase (JAK) inhibitors, and can be given as monotherapy in case of intolerance to MTX, or when treatment with MTX is otherwise inappropriate.. Pfizer Innovative Health Inflammation & Immunology regional president Angela Lukin said: "With a heritage of more than 60 years of providing rheumatoid arthritis treatment options, Pfizer has been a leader in helping to improve the lives of people with inflammatory conditions.. "The approval of Xeljanz in Europe demonstrates Pfizers ongoing commitment to developing medicines ...
A working group convened by the American College of Rheumatology (ACR) has evaluated more than 60 disease activity measures for rheumatoid arthritis (RA). The group narrowed the number of RA disease activity measures and ...
Anti-tumor necrosis factor (anti-TNF) therapies are highly effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but a significant number of patients exhibit only a partial or no therapeutic response. Inflammation alters local and systemic metabolism, and TNF plays a role in this. We undertook this study to determine if the patients metabolic fingerprint prior to therapy could predict responses to anti-TNF agents.Urine was collected from 16 RA patients and 20 PsA patients before and during therapy with infliximab or etanercept. Urine metabolic profiles were assessed using nuclear magnetic resonance spectroscopy. Discriminating metabolites were identified, and the relationship between metabolic profiles and clinical outcomes was assessed.Baseline urine metabolic profiles discriminated between RA patients who did or did not have a good response to anti-TNF therapy according to European League Against Rheumatism criteria, with a sensitivity of 88.9% and a specificity of 85.7%, with several
Find the best rheumatoid arthritis treatment in Gurgaon. Get guidance from medical experts to select heumatoid arthritis treatment in Gurgaon.
Actemra/RoActemra is the only approved anti-IL-6 receptor biologic, available in both intravenous (IV) and subcutaneous (SC) formulations, for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA). Actemra/RoActemra can be used alone or with methotrexate (MTX) in adults who are intolerant to, or have failed to respond to other anti-rheumatic medications. In the most recent update to the European League Against Rheumatism (EULAR) RA management guidelines, Actemra/RoActemra is highlighted as the only biologic that has been repeatedly demonstrated to be superior as a monotherapy over MTX or other conventional disease-modifying antirheumatic drugs (DMARDs). The extensive Actemra/RoActemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra/RoActemra RA SC clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in ...
Actemra / RoActemra is the first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA). Actemra / RoActemra can be used alone or with methotrexate (MTX) in adults who are intolerant to, or have failed to respond to, other anti-rheumatic medications. The most recent European League Against Rheumatism (EULAR) RA management guidelines state that Actemra / RoActemra monotherapy has better efficacy, in regard to signs and symptoms, physical function and joint damage, over MTX or other conventional disease-modifying antirheumatic drugs (DMARDs). The extensive Actemra / RoActemra RA IV clinical development programme included five phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra / RoActemra RA SC clinical development programme included two phase III clinical studies and enrolled more than 1,800 people with RA ...
Natural cures for Rheumatoid Arthritis: Rheumatoid Arthritis Treatment At Kolkata. Rheumatoid Arthritis Aid, Treatments for Rheumatoid Arthritis .
Seattle, Wa (PRWEB) September 02, 2013 -- Paddison Program For Rheumatoid Arthritis is a high-effective rheumatoid arthritis treatment that provides people
2017 Juvenile Rheumatoid Arthritis Treatment Natural Causes Effective All Natural Treatments For Arthritis Dr Axe and Osalteoarthritis - draxe.com. All the tendons and suspensory ligaments which will develop the mutual with each other deteriorate and stretch. Steadily, the mutual will lose it has the figure and alignment. Healthcare doctors are not familiar with precisely what will begin this, however a genetic ingredient seems likely. Even when your passed dow genes wont really induce rheumatoid arthritis symptoms, they will make you weaker in order to external components, such as fungi having confident germs and micro organism, which will trigger the disease.. ...
Switching biologic disease-modifying anti-rheumatic drug (bDMARD) therapy after failure of a first bDMARD for the treatment of psoriatic arthritis (PsA) can be effective, according to a review of the literature and PsA consensus treatment recommendations.. Investigators led by Joseph F. Merola, MD, from Harvard Medical School, Boston, conducted a literature review to determine the efficacy and safety related to switching between bDMARDs in the treatment of PsA, and they evaluated PsA treatment recommendations from national rheumatology societies to identify consensus guidelines on switching.. They noted that "data from the clinical literature on switching bDMARD therapies in PsA are limited," with most studies being observational or retrospective. Treatment responses have been decreased when switching from one tumor necrosis factor inhibitor (TNFi) to a second or third TNFi, and the patient characteristics that predict efficacy after switching arent clear, they wrote online in Seminars in ...
Purpose: Rituximab (RTX) improves signs and symptoms and slows joint damage progression in patients (pts) with rheumatoid arthritis (RA). This study explored the safety of RTX in combination with a TNF inhibitor (etanercept or adalimumab) and MTX in pts with active RA. Methods: Pts with active RA (swollen joint count ≥5 and tender joint count ≥5) receiving a stable dose of etanercept (50 mg qw) or adalimumab (40 mg q2w) and methotrexate (10-25 mg qw) for at least 12 weeks were eligible. Pts were randomized 2:1 and treated with 500 mg RTX or placebo (PLA) on Days 1 and 15. After Wk 24, eligible pts could enter open-label treatment with RTX. The primary endpoint was the proportion of pts who experience ≥1 serious infection through Wk 24. Secondary endpoints evaluated additional safety and efficacy parameters. Results: Fifty-one pts received at least one dose of study treatment (33 RTX, 18 PLA). The concomitant TNF inhibitors were balanced between treatment groups: etanercept (76% vs 78%) and ...
Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA).. The announcement comes after the U.S. Food and Drug Administration approving the therapy in May. The agency authorized Kevzara for adults with RA who failed to responded to, or were unable to tolerate, disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX).. Canada approved Kevzara in January, and the European Union is expected to decide on the drugs Marketing Authorization Application in coming months.. Kevzara is an interleukin-6 receptor antagonist that can be used alone or in combination with MTX or other DMARDs. It is administrated by injection. The recommended dose is 200 mg once every two weeks, but it can be reduced to 150 mg if routine blood tests reveal abnormalities.. Diplomat is the nations largest independent provider of specialty pharmacy services, offering medication management programs for people with complex chronic ...
Comprehensive video overview that covers, transcript, educational quiz, printable action plan, symptoms, causes and treatment options for (Rheumatoid Arthritis Treatment at HealthChoicesFirst.com)
... options like omega 3 fatty acids (plants and coldwater fish) can substantially reduce arthritis pain and other symptoms.
The study is part of a randomized controlled trial comparing standard disease-modifying anti-rheumatic drugs (DMARDs) to anti-tumor necrosis factor (anti-TNF) therapy, Dr. Buch told Reuters Health.. "Longitudinal evaluation with repeat cardiac MRI will allow us to answer whether the abnormalities we have reported improve, whether this depends on reduction in disease activity, and whether it matters how this is achieved, i.e., DMARD versus anti-TNF. We also wish to evaluate other parameters of cardiovascular health, including exercise capacity. This work is part of a wider program of research being conducted in the Leeds CARDIO-AID group," she said.. Epidemiological studies have shown that DMARD treatment reduces the risk of cardiovascular events in RA patients, while anti-TNF treatment is associated with a greater reduction in cardiovascular event risk, Dr. Buch said. Patients with established RA who have reduced disease activity also have lower risk of cardiovascular events, she added.. "In ...
Background/Purpose: To date, although several have been proposed, there are no validated remission criteria in psoriatic arthritis (PsA). Validated criteria for minimal disease activity (MDA) in PsA have been established. This study aimed to compare sensivity and specificity of different potential remission criteria to identify patients in remission as defined by musculoskeletal ultrasound (US).. Methods: In this cross sectional study PsA patients were consecutively recruited from an outpatient clinic. All the patients fulfilled the CASPAR criteria for PsA. The following potential remission criteria were assessed: (1) Disease Activity Index for Psoriatic Arthritis (DAPSA) ≤3.3, (2) Composite Psoriasis Disease Activity Index (CPDAI) ,2, (3) Psoriatic ArthritiS Disease Activity Score (PASDAS) ,2.4 (4) Booleans definition of remission modified for PsA, meeting all of the following criteria: 68 tender joints (TJC68) ≤1, 66 swollen joints (SJC66)≤1, Maastricht Ankylosing Spondylitis Enthesitis ...
Sarilumab is a humanized monoclonal antibody directed against the interleukin-6 (IL-6) receptor intended for the treatment of adults with moderately to severely active rheumatoid arthritis. IL-6 is the most abundant cytokine in the serum and synovial fluid of individuals with rheumatoid arthritis and levels correlate with both disease activity and joint destruction. On May 22, 2017, the U.S. Food and Drug Administration (FDA) approved sarilumab for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Sarilumab may be used as monotherapy or in combination with methotrexate or other conventional DMARDs. Sarilumab is administered at the recommended dosage of 200 milligrams once every 2 weeks as a subcutaneous injection under the guidance of a healthcare professional. An individual may self-inject or a caregiver may administer sarilumab with proper training in the ...
LONDON - Currently, the anti-TFN drugs are in the top ten blockbuster drugs globally. They have been residing upon the words pharma landscape for a long time. As of 2015, the anti-TNF drugs (namely, Remicade & Enbrel, Humira) for the rheumatic disease had totaled sales of over USD 30 billion.. At present, there are more than two dozen tumor necrosis factor inhibitors that are commercially available in the marketplace. Besides, over 150 tumor necrosis factor inhibitors in the clinical pipeline.. The three pharma agents directed against TNF-alpha have been extensively used for management of ankylosing spondylitis, rheumatoid arthritis, etc. The two novel agents used for treatment of such diseases as rheumatoid arthritis and Crohns disease to the marketplace has recently took place.. The usage of TNF-antagonists has demonstrated good results and cleared the way for the further research in this field.. New research report "Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022" ...
Anti-tumor necrosis factor (anti-TNF) drugs are effective against psoriasis, although 20-30% of patients are nonresponders. Few pharmacogenomic studies have been performed to predict the response to anti-TNF drugs in psoriasis. We studied 173 polymorphisms to establish an association with the response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis (N=144). We evaluated the response using PASI75 at 3, 6 and 12 months. The results of the multivariate analysis showed an association between polymorphisms in PGLYR4, ZNF816A, CTNNA2, IL12B, MAP3K1 and HLA-C genes and the response at 3 months. Besides, the results for polymorphisms in IL12B and MAP3K1 were replicated at 6 months. We also obtained significant results for IL12B polymorphism at 1 year. Moreover, polymorphisms in FCGR2A, HTR2A and CDKAL1 were significant at 6 months. This is the first study to show an association with these polymorphisms. However, these biomarkers should be validated in large-scale studies before ...
Rheumatoid arthritis (RA) is a chronic, progressive disorder in many patients. Despite therapy with disease-modifying antirheumatic drugs (DMARDS), including biologic agents, joint erosion and destruction can develop over time. (See.)The major sympto
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
To the Editor: The use of tumor necrosis factor inhibitors (TNFi) for psoriasis was associated with a significant reduction in myocardial infarction incidence and risk,1 and in cardiovascular mortality.2,3 The objective was to assess changes in C-reactive protein (CRP), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT) for patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis exposed to a TNFi with concomitant exposure to methotrexate (MTX) compared with patients exposed to MTX therapy with no TNFi.The full study meth
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7-10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306). ...
In addition to cell death through apoptosis, the Tim-3 pathway could be involved in the induction and/or expansion of Foxp3+ Tregs. Recently, Tim-3 and Gal-9 mRNA levels were shown to positively correlate with Foxp3 mRNA expression in PBMCs of rheumatoid arthritis patients and were found to be significantly higher in patients with low disease activity compared with those with moderate to high disease activity. This suggests that the Tim-3/Gal-9 pathway could exert its suppressive effect on rheumatoid arthritis disease activity by modulation of Foxp3+ Tregs (36). In HSV infection, Tim-3 had been found to be expressed by activated but not naive T cells; ,50% of T cells in HSV-induced ocular lesions in mice express Tim-3, and blocking Tim-3 signaling resulted in more severe lesions (37). Importantly, Gal-9 administration could diminish the severity of ocular lesions by inhibiting Th1 cells and promoting Tregs (37). In this study, we show that in HCV infection, the Tim-3 pathway appears to control ...
TY - JOUR. T1 - Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-Inflammasome. AU - Sode, Jacob. AU - Vogel, Ulla. AU - Bank, Steffen. AU - Andersen, Paal Skytt. AU - Thomsen, Marianne Kragh. AU - Hetland, Merete Lund. AU - Locht, Henning. AU - Heegaard, Niels. AU - Andersen, Vibeke. PY - 2014. Y1 - 2014. N2 - OBJECTIVE: Many patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-α blocking treatment (anti-TNF), but about one third do not respond. The objective of this study was to replicate and extend previously found associations between anti-TNF treatment response and genetic variation in the TNF-, NF-κB- and pattern recognition receptor signalling pathways.METHODS: Forty-one single nucleotide polymorphisms (SNPs), including 34 functional, in 28 genes involved in inflammatory pathways were assessed in 538 anti-TNF naive Danish RA patients with clinical data. Multivariable logistic regression analyses were ...
More than 70 percent of the RA patients in the sample, both cases and controls, had received DMARD treatment--including the popular drug methotrexate (MTX), which was recently linked to increased risk of EBV-positive lymphomas by researchers in France. In this study, however, MTX and other standard DMARDs were not associated with any increase in lymphoma risk, nor were NSAIDS, aspirin, or steroids. Interestingly, lymphoma risk was particularly low among patients who had received frequent corticosteroid injections in inflamed joints, indicating a possible lymphoma-protective role of potent anti-inflammatory drugs. Of all the medical treatments assessed, researchers observed increased lymphoma risk associated only with azathioprine (AZA), which is not regarded as a traditional DMARD for RA and rarely used in current treatment ...
Research is ongoing for effective treatment of the debilitating condition of rheumatoid arthritis. With the approval of a new product, rheumatoid arthritis sufferers hold out the hope that it will be effective for them. Even after release, the pharmaceuticals are the subject of ongoing evaluation. A new study was conducted to compare the efficacy of abatacept to adalimumab both with background methotrexate. Researchers affiliated with Brigham and Womens Hospital, Boston, Massachusetts published their findings online on November 20 in the journal Arthritis and rheumatism.. The researchers noted that a need exists for comparative studies to provide evidence-based treatment guidance for biologics in rheumatoid. Therefore, the designed the first head-to-head study in rheumatoid arthritis, which compared subcutaneous abatacept versus adalimumab both with background methotrexate. The primary end point was the ACR20 response at one year. The ACR score is a scale to measure change in rheumatoid ...
BACKGROUND: Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known. METHODS: We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-alpha, in intravenous doses of 3 or 10 mg per kilogram of body weight every 4 or 8 weeks in combination with oral methotrexate for 54 weeks. We assessed clinical responses with use of the criteria of the American College of Rheumatology, the quality of life with a health-status questionnaire, and the effect on joint damage radiographically. RESULTS: The combination of infliximab and methotrexate was well tolerated and resulted in a sustained reduction in the symptoms and signs of rheumatoid arthritis that was significantly greater than the reduction associated with
Rheumatoid Arthritis Treatment - how to make simple Anti inflammation Ginger Paste using Ginger, Lemon, Coriander powder, Cumin powder, Black pepper, Black Salt & Sugar Candy Paste
Abstract In this manuscript, a clinical case of a patient treated with adalimumab for Behcets disease develops lichen planopilaris. A variety of mucocutaneous lichenoid eruptions have recently been described in association with tumor necrosis factor alpha inhibitors. The authors briefly discuss the clinical and pathological presentation of lichen planopilaris as well as a potential pathogenesis of cutaneous adverse effects seen as the result of tumor necrosis factor alpha inhibitor therapy. They review all case reports of lichen planopilaris occurring on tumor necrosis factor alpha inhibitors and suggest its classification as a fourth recognized pattern on this therapy. (J Clin Aesthet Dermatol. 2015;8(6):45-49.). The systemic adverse effects of tumor necrosis factor alpha (TNF) inhibitors are well known. Recently, attention has been directed to the potential and often paradoxical cutaneous adverse effects seen in association with TNF alpha inhibitors including lichen planus-like eruptions, ...
Therapeutic approaches to generalized pustular psoriasis and psoriatic arthritis are discussed separately. Data are limited on the efficacy of biologic agents other than infliximab for the treatment of erythrodermic psoriasis. Key words: drug therapy; psoriasis. Second-line systemic therapies for PPPP are the biologic agents, alefacept, adalimumab, etaner- cept, and infliximab (Fig 5). In other forms of psoriasis, the use of etanercept, as that of other biological therapies, has been published in an isolated way with satisfactory results. Keywords. Generalized pustular psoriasis-Von Zumbusch, Palmoplantar psoriasis, Hallopeau acropustulosis perstan, Erythrodermal psoriasis, Etanercept. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequencial use of infliximab and adalimumab. Biologic therapies, including tumor necrosis factor inhibitors, can be effective for severe ...
In a previous article I discussed a Treatment of acute gouty Arthritis (GA). Your next Ill focus on Treatment late chronic disease. The aims of chronic GA Treatment should be prevent recurrent attacks by reducing the serum uric acid (UA) properly introducing 6mgs/dl, and addressing other associated medical conditions which could be aggravating GA. These contain obesity, high blood pressure, diabetes, drugs the patient are really taking that can elevate UA that is to say diuretics, and OsteoArthritis. With frequent GA, patient can develop extended problems including the emergence of tophi (deposits of UA along side the skin and inside vigorous organs), joint destruction, vesica stones, and kidney breakdown. The Treatment of lingering GA involves dietary sessions, medication adjustment, and specific medicines to remedy GA. GA medicines reduce serum UA. They do this from various mechanisms including reducing the production of uric acid, increasing the removal of uric acid through the kidneys, and ...
Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol, 151 (2004), pp. 3-17. Medline. 4. D. Thaci. Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects 1; all other biologics are recommended for second-line therapy 2-4. Currently, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe 2-4. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Article September 2004 British Journal of Dermatology. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17. Biologic agents ...
Aims: Temporomandibular disorders (TMD) represent a heterogeneous group of inflammatory or degenerative diseases of the stomatognatic system, with algic and/or dysfunctional clinical features involving temporomandibular joint (TMJ) and related masticatory muscles. Rheumatoid Arthritis (RA) is an autoimmune polyarthritis characterized by the chronic inflammation of synovial joints and oral implications such as hyposalivation, difficulty in swallowing and phoning, feeling of burning mouth, increased thirst, loss of taste or unpleasant taste and smell, dental sensitivity.. The aim of this observational study was to investigate the prevalence of TMD symptoms and signs as well as oral implications in patients with Early Rheumatoid Arthritis (ERA), that is a RA diagnosed within 12 months, compared with a control group.. Methods: The study group included 52 ERA patients (11 men, 41 women) diagnosed according to the 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis. A randomly selected ...
In most patients, erythema migrans skin lesions, an early disease manifestation, yielded positive culture and PCR results for the Lyme disease agent. Similarly, the majority of pre-treatment synovial fluid samples in patients with Lyme arthritis, a late disease manifestation, had positive PCR results for B. burgdorferi DNA. Patients with Lyme arthritis were treated with oral antibiotics for one or two months, and in those for whom the arthritis did not resolve, IV antibiotics were administered for an additional month. If they had persistent arthritis despite three months of antibiotics, patients were treated with non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs).. About 30% of patients with persistent arthritis, despite the three month antibiotic regimen, still had positive PCR results for 4-9 months after the start of antibiotics. However, positive PCR results in the post-antibiotic period did not correlate with relapse or duration of arthritis. ...

ANTIRHEUMATIC AGENTS | The Journal of RheumatologyANTIRHEUMATIC AGENTS | The Journal of Rheumatology

Rheumatoid Arthritis: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden Alma B. Pedersen, Anil ... Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients ... The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with ... Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and ...
more infohttp://www.jrheum.org/keyword/antirheumatic-agents

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate...Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate...

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate ... Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate ... Anti-TNF agents provided a significant higher probability of achieving an ACR50 response at 6 months than the non-anti-TNF ... If more than one RCT was available for a given agent, the data were pooled across the trials using the random effect model ( ...
more infohttps://ard.bmj.com/content/70/2/266?ijkey=853e6bcf5238a8dd1fcc7a7016c703cad705a2c4&keytype2=tf_ipsecsha

Mercaptyl
        -
        Antidotes,  Antirheumatic Agents,  Chelating Agents,  ATC:M01CC01Mercaptyl - Antidotes, Antirheumatic Agents, Chelating Agents, ATC:M01CC01

Penicillamine is a chelating agent used in the treatment of Wilsons disease. It is also used to reduce cystine excretion in ...
more infohttp://pharmacycode.com/Mercaptyl.html

Penicillamine
        -
        Antidotes,  Antirheumatic Agents,  Chelating Agents,  ATC:M01CC01Penicillamine - Antidotes, Antirheumatic Agents, Chelating Agents, ATC:M01CC01

Penicillamine is a chelating agent used in the treatment of Wilsons disease. It is also used to reduce cystine excretion in ...
more infohttp://pharmacycode.com/Penicillamine.html

Antiinflammatory/antirheumatic agents in combination with corticosteroids | Antiinflammatory/antirheumatic agents in...Antiinflammatory/antirheumatic agents in combination with corticosteroids | Antiinflammatory/antirheumatic agents in...

Antiinflammatory/antirheumatic agents in combination , Antiinflammatory and antirheumatic products Brokerage service for ... Antiinflammatory/antirheumatic agents in combination. *Antiinflammatory/antirheumatic agents in combination with ... Agents acting on the renin-angiot.. Ace inhibitors, plain Ace inhibitors, plain ... Beta blocking agents Beta blocking agents Beta blocking agents, non-selecti.. Beta blocking agents, selective ...
more infohttps://goldpharma.cn/article/11094/lang/ENGLISH/t/antiinflammatory/antirheumatic%20agents%20in%20combination%20with%20corticosteroids/

Other antiinflammatory and antirheumatic agents non-steroids | Antiinflammatory and antirheumatic products non-steroids |...Other antiinflammatory and antirheumatic agents non-steroids | Antiinflammatory and antirheumatic products non-steroids |...

Antiinflammatory and antirheumatic products non-steroids , Antiinflammatory and antirheumatic products Brokerage service for ... Agents acting on the renin-angiot.. Ace inhibitors, plain Ace inhibitors, plain ... Beta blocking agents Beta blocking agents Beta blocking agents, non-selecti.. Beta blocking agents, selective ... Other antiinflammatory and antirheumatic agents non-steroids , ... Lipid modifying agents Lipid modifying agents, plain Hmg coa ...
more infohttps://goldpharma.cn/article/11093/lang/ENGLISH/t/other%20antiinflammatory%20and%20antirheumatic%20agents,%20non-steroids/

A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents...A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents...

A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents ... A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents ... Objective: Treatments for psoriatic arthritis (PsA) range from high-cost agents like tumour necrosis factor (TNF) inhibitors ... Results: We identified 32 potentially relevant RCTs; 14 were excluded because they involved unused agents, were unblinded, were ...
more infohttp://ard.bmj.com/content/early/2007/09/07/ard.2007.072652

Pharmocology Flashcards by E B | BrainscapePharmocology Flashcards by E B | Brainscape

Disease-modifying Antirheumatic Agents. Used for rheumatic disease - early in he progression of the disease. Inhibit the immune ... Aspirin - non opiod agent, anti-inflammatory and reduction of risk of myocardial infarction Potential of Reye syndrome in ...
more infohttps://www.brainscape.com/flashcards/pharmocology-998245/packs/1681674

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?  - PubMed - NCBIAfter treat-to-target: can a targeted ultrasound initiative improve RA outcomes? - PubMed - NCBI

Antirheumatic Agents/therapeutic use*. *Arthritis, Rheumatoid/diagnostic imaging*. *Arthritis, Rheumatoid/drug therapy* ... remission can be achieved with tight control of inflammation and early use of disease modifying agents. The importance of ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/22562979

Drug-induced ocular side effects (Book, 2001) [WorldCat.org]Drug-induced ocular side effects (Book, 2001) [WorldCat.org]

3. Analgesics, Narcotic antagonists, and agents used to treat arthritis: Agents used to treat gout. Antirheumatic agents. Mild ... Antifungal agents. Antileprosy agents. Antimalarial agents. Antiprotozoal agents. Antitubercular agents --. 2. Agents affecting ... Antifungal agents. Antileprosy agents. Antimalarial agents. Antiprotozoal agents. Antitubercular agents -- 2. Agents affecting ... Oxytocic agents --. 9. Homeostatic and nutrient agents: Agents used to treat hyperglycemia. Vitamins --. 10. Agents used to ...
more infohttp://www.worldcat.org/title/drug-induced-ocular-side-effects/oclc/44129071

Effects of Abatacept in Patients With Early Rheumatoid Arthritis - Full Text View - ClinicalTrials.govEffects of Abatacept in Patients With Early Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov

Dermatologic Agents. Enzyme Inhibitors. Folic Acid Antagonists. Immunosuppressive Agents. Immunologic Factors. Antirheumatic ... Abortifacient Agents, Nonsteroidal. Abortifacient Agents. Reproductive Control Agents. Physiological Effects of Drugs. ... Previous treatment with any conventional or biologic Disease-modifying anti rheumatic drugs (DMARD) ...
more infohttps://clinicaltrials.gov/ct2/show/NCT02504268?term=Orencia&cond=%22Connective+Tissue+Disease%22&intr=%22Abatacept%22&rank=80

A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache...A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache...

Anti-Inflammatory Agents, Non-Steroidal. Anti-Inflammatory Agents. Antirheumatic Agents. Cyclooxygenase Inhibitors. Enzyme ... Sensory System Agents. Peripheral Nervous System Agents. Physiological Effects of Drugs. Antipyretics. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT03472872

Gold Sodium Thiomalate use while Breastfeeding | Drugs.comGold Sodium Thiomalate use while Breastfeeding | Drugs.com

4. Ramsey-Goldman R, Schilling E. Optimum use of disease-modifying and immunosuppressive antirheumatic agents during pregnancy ... Antirheumatic drugs in pregnancy and lactation. Baillieres Clin Rheumatol. 1990;4:157-71. PMID: 2282661 ...
more infohttps://www.drugs.com/breastfeeding/gold-sodium-thiomalate.html

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer - Full Text View - ClinicalTrials.govAllogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer - Full Text View - ClinicalTrials.gov

Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. Antirheumatic Agents. Antineoplastic Agents, ... Antineoplastic Agents. Myeloablative Agonists. Enzyme Inhibitors. Antifungal Agents. Anti-Infective Agents. Dermatologic Agents ... Alkylating Agents. Molecular Mechanisms of Pharmacological Action. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00056095?term=stem+cell+kidney&rank=39

Certolizumab Pegol (Cimzia) use while BreastfeedingCertolizumab Pegol (Cimzia) use while Breastfeeding

Antirheumatic Agents Gastrointestinal Agents Administrative Information. LactMed Record Number. 752 Last Revision Date. ... A total of 102 women were exposed to an anti-TNF agent and 59 were exposed to a thiopurine plus an anti-TNF agent. The use of ... Detection of biologic agents in breast milk and implication for infection, growth and development in infants born to women with ... Infants exposed to both a thiopurine and an anti-TNF agent had a 50% increase in the number of infections between 9 and 12 ...
more infohttps://www.drugs.com/breastfeeding/certolizumab-pegol.html

Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in...Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in...

Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in ...
more infohttps://www.hindawi.com/journals/isrn/2013/907085/ref/

A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid...A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid...

0/Antirheumatic Agents; 0/Collagen Type II; 59-05-2/Methotrexate From MEDLINE®/PubMed®, a database of the U.S. National Library ... Antirheumatic Agents / adverse effects, therapeutic use*. Arthritis, Rheumatoid / drug therapy*. Chickens. Collagen Type II / ...
more infohttp://www.biomedsearch.com/nih/randomized-double-blind-multicenter-controlled/18576295.html

Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice.Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice.

Antirheumatic Agents / pharmacology, therapeutic use. Arthritis, Experimental / drug therapy*, immunology, physiopathology. ... 0/Antigen-Antibody Complex; 0/Antirheumatic Agents; 0/Cytokines; 0/Immunoglobulins; 0/Receptors, IgG; 0/Staphylococcal Protein ... Thus, therapeutic agents designed to harness all of these properties may be an effective treatment for arthritis, by targeting ... In addition, the efficacy of SPA as a therapeutic agent was evaluated in murine collagen-induced arthritis (CIA).. RESULTS: SPA ...
more infohttp://www.biomedsearch.com/nih/Co-opting-endogenous-immunoglobulin-regulation/22127707.html

MEDLINE - Resultado p gina 1
	MEDLINE - Resultado p gina 1

0 (Antirheumatic Agents); 0 (Pyridones); D7NLD2JX7U (pirfenidone); H806S4B3NS (Oxyphenbutazone). [Em] M s de entrada:. 0707. ... 0 (Anti-Inflammatory Agents, Non-Steroidal); GN5P7K3T8S (Phenylbutazone); H806S4B3NS (Oxyphenbutazone). [Em] M s de entrada:. ... 0 (Anti-Inflammatory Agents, Non-Steroidal); GN5P7K3T8S (Phenylbutazone); H806S4B3NS (Oxyphenbutazone). [Em] M s de entrada:. ... 0 (Anti-Inflammatory Agents, Non-Steroidal); GN5P7K3T8S (Phenylbutazone); H806S4B3NS (Oxyphenbutazone). [Em] M s de entrada:. ...
more infohttp://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&nextAction=lnk&base=MEDLINE&lang=p&format=detailed.pft&indexSearch=EX&exprSearch=D03.383.129.539.850.777.700

Liroken (Diclofenac Sodium) Kendrick LaboratoriosLiroken (Diclofenac Sodium) Kendrick Laboratorios

Antirheumatic agents *Cancer drugs *Cyclooxygenase-2 (COX-2) inhibitors *Dermatological remedies *Medicines acting on musculo- ... Nonsteroidal antiimflammatory agents *Nonsteroidal anti-inflammatory drugs (NSAIDs) *Ophthalmic decongestants, anesthetics, ...
more infohttps://drugs-about.com/drugs-l/liroken.html

Lene Dreyer
     - Aalborg Universitets forskningsportalLene Dreyer - Aalborg Universitets forskningsportal

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis ...
more infohttps://vbn.aau.dk/da/persons/142641
  • The objective of the present work was to compare the efficacy of biologicals (anti-tumour necrosis factor (TNF) agents, rituximab, abatacept, tocilizumab) in patients with RA with active disease and (i) an inadequate response (IR) to methotrexate (IR-MTX), (ii) an IR to anti-TNF agents (IR-anti-TNFs) using indirect comparisons. (bmj.com)
  • Methods Randomised clinical trials were identified examining the efficacy of a biological agent in RA at 6 months in patients with an IR-MTX or with an IR-anti-TNF. (bmj.com)
  • 14 were excluded because they involved unused agents, were unblinded, were not placebo-controlled and enrolled patients with other diseases. (bmj.com)
  • For patients with rheumatoid arthritis (RA), remission can be achieved with tight control of inflammation and early use of disease modifying agents. (nih.gov)
  • We did not include anti-IL-1 biologicals (anakinra) in this meta-analysis because these agents are not widely available for the treatment of RA. (bmj.com)
  • Penicillamine is a chelating agent used in the treatment of Wilson's disease. (pharmacycode.com)